Overall survival results for durvalumab and savolitinib in metastatic papillary renal cancer.

Cristina Suarez Rodriguez,James Larkin,Poulam M. Patel,B.P. Valderrama,Alejo Rodriguez-Vida,Hilary Glen,Fiona C. Thistlethwaite,Christy Ralph,Gopalakrishnan Srinivasan,Maria Jose José Mendez Vidal,Abigail Carter,Charlotte Tyson,Aaron Prendergast,Kelly Mousa,Thomas Powles

Overall survival results for durvalumab and savolitinib in metastatic papillary renal cancer.

2020

Cristina Suarez Rodriguez
James Larkin
Poulam M. Patel
B.P. Valderrama
Alejo Rodriguez-Vida
Hilary Glen
Fiona C. Thistlethwaite
Christy Ralph
Gopalakrishnan Srinivasan
Maria Jose José Mendez Vidal
Abigail Carter
Charlotte Tyson
Aaron Prendergast
Kelly Mousa
Thomas Powles

619Background: There is a strong rationale for investigating MET and PD-L1 inhibition in metastatic papillary renal cancer (PRC). We previously reported response rates (RR) and progression free sur...

Keywords:

Savolitinib
Oncology
Durvalumab
Pathology
Cancer
Internal medicine
Medicine
overall survival

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations